What is a peptide?
A peptide is a chain of amino acids that play various roles in the body such as:
- Hormone Regulation
- Immune Function
- Tissue Repair
- Appetite Control
- Pain Regulation
- Muscle Growth/Repair
These chains of amino acids are made to bind to different receptors in the body, this is dependent on the chemical makeup of the peptide. Those receptors are what trigger certain functions in the body
Common misconceptions:
- Peptides will grow bones- Oral Peptides are effective
Routes of administration
Intranasal = Through your nose
Intranasal administration is an effective way to ingest peptides
They cross the blood brain barrier effectively, making intranasal a preferred route for cognitive peptides
Pros:
- Quicker onset compared to subq and IM
- No injections/needles
- Breaches blood brain barrier effectively
- More practical than injecting
Cons:
- Less absorption of the peptide (typical bioavailablity 10-40%)
- Shorter duration of action
- Nasal irritation and damage over time
Peptides mainly used intranasally are nootropics, such as semax, selank, and noopept
NEVER USE:
BPC-157, TB-500 (Thymosin Beta-4), CJC-1295 (without DAC), Ipamorelin, GHRP-6, GHRP-2, PEGylated peptides/long-acting GH analogs, IGF-1, IGF-1 LR3, Melanotan II, Melanotan I, Follistatin, Thymosin Alpha-1, full-length exogenous GH
these peptides are too large to be absorbed properly through your olfactory or trigeminal pathway, meaning realistically no bioavailability
Intranasal administration is an effective way to ingest peptides
They cross the blood brain barrier effectively, making intranasal a preferred route for cognitive peptides
Pros:
- Quicker onset compared to subq and IM
- No injections/needles
- Breaches blood brain barrier effectively
- More practical than injecting
Cons:
- Less absorption of the peptide (typical bioavailablity 10-40%)
- Shorter duration of action
- Nasal irritation and damage over time
Peptides mainly used intranasally are nootropics, such as semax, selank, and noopept
NEVER USE:
BPC-157, TB-500 (Thymosin Beta-4), CJC-1295 (without DAC), Ipamorelin, GHRP-6, GHRP-2, PEGylated peptides/long-acting GH analogs, IGF-1, IGF-1 LR3, Melanotan II, Melanotan I, Follistatin, Thymosin Alpha-1, full-length exogenous GH
these peptides are too large to be absorbed properly through your olfactory or trigeminal pathway, meaning realistically no bioavailability
Subcutaneous often referred to as subq are injections directly under the skin, into the fatty tissue between the skin and muscle
Pros:
- High Bioavailability
- Steady Release
- Easy self administration
Cons:
- Slow Onset
- Risk of infection (Low but still possible)
Most peptides will be administered subcutaneously, due to the high bioavailability and sustained release which will limit side effects as well as make the dosing is consistent each time
Always sterilize petpide vial stopper, and injection site. Never reuse needles
Use 27-31g needles, (I find 29 to be the sweet spot)
Pros:
- High Bioavailability
- Steady Release
- Easy self administration
Cons:
- Slow Onset
- Risk of infection (Low but still possible)
Most peptides will be administered subcutaneously, due to the high bioavailability and sustained release which will limit side effects as well as make the dosing is consistent each time
Always sterilize petpide vial stopper, and injection site. Never reuse needles
Use 27-31g needles, (I find 29 to be the sweet spot)
Intramuscular injections are administered directly into muscle tissue such as delts, lats, or quads
View attachment human-skin-intramuscular-injection-vector.jpg
Pros:
- Faster onset than subq
- High bioavailability
- More suitable for certain peptides
Cons:
- More painful
- Risk of infection
- Risk of hitting nerve
Peptides that act on muscle tissue such as IGF-1 LRG and Myostatin inhibitors are preferred IM for best results
View attachment human-skin-intramuscular-injection-vector.jpg
Pros:
- Faster onset than subq
- High bioavailability
- More suitable for certain peptides
Cons:
- More painful
- Risk of infection
- Risk of hitting nerve
Peptides that act on muscle tissue such as IGF-1 LRG and Myostatin inhibitors are preferred IM for best results
intranasal peptides must be reconstituted and inserted into a spray bottle
Subq and IM also need to be reconstituted
Great guide on reconstitution Biomaxx's guide
Sourcing
Sourcing peptides is a lot easier than things like steroids or prescription medications
Most of the US Based companies you see buy their peptides from china and resell them to you at a marked up price
The best way is to find a Chinese gray market supplier, make sure it is reputable with third party testing
Look for Janoshik third party testing
You will have to pay with bitcoin
shipping cost is high, but you save much more money on the peptides themselves
If I want a vial fast, I use this Site as all of these sources have third party testing and you can sort by price per mg (even though they use chinese peptides too)
- You can get alcohol swabs at any store
Most of the US Based companies you see buy their peptides from china and resell them to you at a marked up price
For example:
Buy a kit (10 vials) of Ghk-cu 100mg for $60
Resell them to you for $60-80 per vial
Buy a kit (10 vials) of Ghk-cu 100mg for $60
Resell them to you for $60-80 per vial
The best way is to find a Chinese gray market supplier, make sure it is reputable with third party testing
Look for Janoshik third party testing
You will have to pay with bitcoin
shipping cost is high, but you save much more money on the peptides themselves
If I want a vial fast, I use this Site as all of these sources have third party testing and you can sort by price per mg (even though they use chinese peptides too)
- You can buy syringes on amazon
- you can also get them in store but most places make you show id and you must be above 18 (walgreens,cvs,walmart) so this won’t be possible for most of you
something like this will work
- you can also get them in store but most places make you show id and you must be above 18 (walgreens,cvs,walmart) so this won’t be possible for most of you
something like this will work
- You can get alcohol swabs at any store
ALL MAJOR RESEARCH PEPTIDES
Metabolic Research
Metabolic Research
- Description: A peptide fragment derived from the Growth Hormone molecule, studied for its ability to stimulate lipolysis (fat-burning) without affecting GH or blood sugar levels.
- Dosing: Research protocols typically use 200-500 mcg administered once daily, often before exercise.
- Route: Subcutaneous (SC) injection or sometimes compounded into Sublingual troches.
- Side Effects: Generally reported as well-tolerated, but some users experience headache, mild nausea, or injection site reactions.
- Risks: FDA Category 2 substance (compounding restricted); lack of final FDA approval for human use.
- Description: A critical coenzyme present in every cell. It is vital for cellular energy production (ATP), DNA repair, and activating sirtuins (proteins linked to longevity). While not a peptide, it is a common longevity therapeutic.
- Dosing: IV/Injectable: Clinical infusion doses typically range from 250 mg to 1000 mg per session. Oral: Precursor supplements (like NMN or NR) are dosed from 250 mg to 1000 mg per day.
- Route: Intravenous (IV) infusion (for maximum systemic absorption), Intramuscular (IM) injection, or Oral precursor supplements (NMN/NR).
- Side Effects: Rapid IV infusion can cause chest pressure, heart palpitations, or stomach cramping (known as the "NAD Flush"), requiring a slower drip rate. Oral forms are generally mild.
- Risks: Very low risk when administered correctly and slowly. Risks are mainly associated with improper IV administration or non-sterile sourcing of the injectable product.
- Description: A mitochondrial-encoded peptide studied for its role in metabolic health, glucose metabolism, and insulin sensitivity (mimicking effects of exercise).
- Dosing: Experimental doses range from 5-10 mg, typically administered 2-3 times per week.
- Route: Subcutaneous (SC) injection.
- Side Effects: Reports include injection site irritation, increased heart rate, and insomnia; very little human safety data available.
- Risks: FDA Category 2 substance (compounding restricted); unknown long-term effects of manipulating mitochondrial signaling.
- Description: An FDA-approved GLP-1 receptor agonist used for Type 2 Diabetes management and chronic weight management.
- Dosing: Starts low (e.g., 0.25 mg weekly) and is gradually titrated up to a maintenance dose of 1-2.4 mg weekly.
- Route: Subcutaneous (SC) injection (weekly) or an Oral tablet (daily).
- Side Effects: Nausea, vomiting, diarrhea, abdominal pain, and constipation are very common.
- Risks: Potential for Pancreatitis and risk of Thyroid C-cell tumors.
- Description: An FDA-approved dual agonist for GLP-1 and GIP receptors, highly effective for Type 2 Diabetes and chronic weight management.
- Dosing: Starts low (e.g., 2.5 mg weekly) and is gradually titrated up to a maximum of 10-15 mg weekly.
- Route: Subcutaneous (SC) injection (weekly).
- Side Effects: Very common nausea, vomiting, diarrhea, decreased appetite, and constipation, especially during dose escalation.
- Risks: Potential for Pancreatitis and risk of Thyroid C-cell tumors (seen in animal studies).
- Description: An experimental triple-agonist peptide targeting GLP-1, GIP, and Glucagon receptors, showing superior weight loss results in clinical trials. Not FDA-approved.
- Dosing: Clinical trials range from 1 mg to 12 mg weekly, with a gradual dose escalation schedule. Anecdotal research often follows this schedule.
- Route: Subcutaneous (SC) injection (weekly).
- Side Effects: High incidence of gastrointestinal side effects (nausea up to 63%, vomiting, diarrhea), which are dose-dependent. Potential for a transient increase in resting heart rate.
- Risks: Long-term safety is unknown. Serious adverse events (pancreatitis, gallstones) were reported in trials. High risk of unregulated purity.
GH/ GH SECRETAGOUGES
- Description: A stack combining a GHRH analog (CJC-1295) and a selective GHRP (Ipamorelin) to stimulate natural GH pulses from the pituitary gland.
- Dosing: CJC-1295 (w/ DAC): Research protocols typically use 1-2 mg per week. Ipamorelin: Often 200-300 mcg, 1-3 times daily.
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, flushing, headache, and transient water retention. The long-term safety profile is unestablished.
- Risks: FDA Category 2 substance (compounding restricted); potential for IGF-1 elevation and promoting the growth of existing cancerous cells.
- Description: A synthetic Growth Hormone-Releasing Hormone (GHRH) analog that includes a Drug Affinity Complex (DAC), which binds it to plasma proteins, greatly extending its half-life to about 8 days. It stimulates the pituitary gland to release GH.
- Dosing: Research protocols typically use 1-2 mg per week, administered in a single weekly injection. It is often stacked with a daily GHRP like Ipamorelin for optimal pulsatility.
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, flushing, headache, and transient water retention (edema). Long-term safety is unestablished due to limited clinical trials.
- Risks: FDA Category 2 substance (compounding restricted due to safety concerns); risk of unregulated purity; potential for uncontrolled elevation of GH and IGF-1 if dosed incorrectly, which may be linked to cancer risk.
- Description: A synthetic GHRH analog that stimulates the pituitary gland to release GH. Modified GRF (without DAC) has a short half-life, creating a natural pulsatile release.
- Dosing: Modified GRF (without DAC): 100-500 mcg, 1-3 times daily (always stacked with a GHRP). CJC-1295 (with DAC): 1-2 mg per week (longer half-life).
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, flushing, headache, and transient water retention (edema).
- Risks: FDA Category 2 substance (compounding restricted); potential for IGF-1 elevation (high levels can be harmful).
- Description: A highly selective GHRP that mimics Ghrelin, promoting GH release with minimal stimulation of cortisol or prolactin at typical doses. The preferred GHRP in most stacks.
- Dosing: Often 200-300 mcg, 1-3 times daily (typically stacked with a GHRH Analog).
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, headache, vivid dreams, and increased appetite (mild).
- Risks: FDA Category 2 substance (compounding restricted); long-term safety is unknown.
- Description: The full, FDA-approved recombinant form of Growth Hormone, used medically for GH deficiency. Widely misused for performance.
- Dosing: Clinical doses are typically 0.2-1.0 mg (0.6-3.0 IU) per day, highly dependent on medical indication.
- Route: Subcutaneous (SC) injection.
- Side Effects: Joint pain, fluid retention (edema), carpal tunnel syndrome, numbness/tingling; more common at higher doses.
- Risks: Serious risks include insulin resistance/Type 2 diabetes, acromegaly, and increased risk of promoting tumor growth.
- Description: An FDA-approved GHRH analog used specifically to reduce excess visceral fat (lipodystrophy) in HIV patients.
- Dosing: 2 mg administered once daily.
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, joint pain, peripheral edema (fluid retention), and potential for hyperglycemia (high blood sugar).
- Risks: Contraindicated in active malignancy. Requires medical supervision and blood monitoring.
- Description: A potent, modified research variant of the main mediator of GH action, promoting tissue growth. Mecasermin is the FDA-approved version.
- Dosing: Experimental doses for IGF-1 LR3 are typically 20-80 mcg per day.
- Route: Subcutaneous (SC) injection or Intramuscular (IM) (often localized).
- Side Effects: Hypoglycemia (low blood sugar), dizziness, lethargy, muscle soreness, and injection site reactions.
- Risks: Serious risk of hypoglycemia (if not timed with carbohydrates) and potential for promoting the growth of existing cancerous cells.
- Description: A potent, synthetic GHRP that stimulates GH release strongly, also known to elevate cortisol and prolactin significantly.
- Dosing: Research protocols range from 100-300 mcg, 2-3 times daily.
- Route: Subcutaneous (SC) injection, sometimes Intranasal.
- Side Effects: Strong appetite stimulation, noticeable elevations in cortisol and prolactin, and fatigue.
- Risks: FDA Category 2 substance (compounding restricted); stronger side effect profile than Ipamorelin.
- Description: An older, potent GHRP that strongly stimulates GH release and the Ghrelin receptor, leading to a significant increase in hunger.
- Dosing: Research protocols range from 50-300 mcg, 2-3 times daily.
- Route: Subcutaneous (SC) injection.
- Side Effects: Significant increase in hunger, potential elevations of cortisol and prolactin (endocrine disruption risk), and headache.
- Risks: FDA Category 2 substance (compounding restricted); high risk of unregulated purity.
- Description: One of the most potent GHRPs, known for high efficacy but also a high potential for receptor desensitization (down-regulation) with prolonged use.
- Dosing: Research doses are often 100-300 mcg, 2-3 times daily.
- Route: Subcutaneous (SC) injection.
- Side Effects: Strong stimulation often results in elevated cortisol and prolactin; rapid receptor desensitization over time.
- Risks: FDA Category 2 substance (compounding restricted); long-term risks associated with severe receptor down-regulation.
- Description: A shorter-acting, older GHRH analog (GHRH 1-29 fragment) used to stimulate natural GH release.
- Dosing: Typically 200-500 mcg administered nightly.
- Route: Subcutaneous (SC) injection.
- Side Effects: Injection site reactions, headache, dizziness, and flushing.
- Risks: Risks tied to the unregulated purity of compounding formulations.
TISSUE REPAIR
- Description: A synthetic pentadecapeptide studied for systemic regenerative and cytoprotective effects, often used for tendon, ligament, muscle, and gastrointestinal healing.
- Dosing: Research protocols typically use 150-500 mcg, administered once or twice daily. Oral dosing is similar.
- Route: Subcutaneous (SC) injection (localized or systemic) or Oral capsules.
- Side Effects: Local irritation, pain, or redness at the injection site are the most common; long-term safety is unknown.
- Risks: FDA Category 2 substance (compounding restricted); lack of robust human safety data and banned by WADA.
- Description: A synthetic version of a naturally occurring peptide involved in cell migration, tissue protection, and systemic repair of damaged tissues.
- Dosing: Highly variable; protocols often start with 2-5 mg twice weekly (loading), followed by 2-5 mg bi-weekly (maintenance).
- Route: Subcutaneous (SC) injection or Intramuscular (IM) injection.
- Side Effects: Tiredness or lethargy, mild headaches, and injection site irritation.
- Risks: Concern regarding its potential to influence tumor growth (due to pro-angiogenic properties); unapproved by FDA.
NOOTROPICS
- Description: A potent hexapeptide derivative of Angiotensin IV, studied for strong procognitive/neurogenic activity, potentially enhancing the formation of new synapses.
- Dosing: Anecdotal research doses often use 1-10 mg per day.
- Route: Oral capsules, Sublingual drops/troches, or Topical/Transdermal creams.
- Side Effects: Headache, overstimulation, and anxiety have been anecdotally reported.
- Risks: Virtually no human safety data exists, with unpredictable neuroactive effects and extreme regulatory risk.
- Description: A heptapeptide analog of the ACTH(4-10) fragment. It is primarily studied for its neuroprotective and nootropic (cognitive-enhancing) effects, often used to improve memory, attention, and recovery from stroke or TBI.
- Dosing: Research and foreign clinical doses typically range from 300 mcg to 3 mg per day, often administered in divided doses.
- Route: Primarily Intranasal spray; also rarely available for Subcutaneous (SC) injection.
- Side Effects: Generally well-tolerated. Can cause overstimulation or anxiety in sensitive users; local irritation from nasal spray.
- Risks: Not FDA-approved in the US. The FDA warns of risks associated with immunogenicity and purity when sourced from unregulated vendors.
- Description: A synthetic, proline-containing dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) created as an analog of the traditional nootropic Piracetam. It is studied for its strong procognitive, neuroprotective, and anxiolytic properties, often linked to increased expression of BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor).
- Dosing: Clinical and research doses are significantly lower than Piracetam, typically ranging from 10 mg to 30 mg per day, often split into two or three doses. High doses are generally not recommended due to increased side effects.
- Route: Primarily Oral capsule or powder, as it has high bioavailability. Also sometimes administered Sublingual (under the tongue) or Intranasal.
- Side Effects: Generally considered well-tolerated. Common side effects include headache (often treated with a choline supplement), restlessness, insomnia, gastrointestinal discomfort, or mild irritability/anxiety (at higher doses).
- Risks: Not FDA-approved for sale as a drug in the US (though available as a supplement). Long-term safety is not established in healthy populations. There are theoretical risks of overstimulation or unpredictable psychiatric adverse effects in sensitive individuals or those with underlying mental health conditions.
- Description: A synthetic heptapeptide analog of the immunomodulatory peptide tuftsin. It is widely used for its anxiolytic (anti-anxiety) and nootropic effects, often compared to benzodiazepines but without the same dependency or side effects.
- Dosing: Typical doses range from 300 mcg (intranasal) to 1.5 mg (injectable) per day, often cycled (e.g., one month on, one month off).
- Route: Primarily Intranasal spray; also available for Subcutaneous (SC) injection.
- Side Effects: Generally well-tolerated. Can cause overstimulation or transient dizziness; minimal reported side effects compared to traditional anxiolytics.
- Risks: Not FDA-approved in the US. FDA Category 2 substance (compounding restricted) due to risks of immunogenicity and lack of safety data.
Sexual Health
- Description: A synthetic peptide analog of 1$\alpha$-MSH (alpha-melanocyte-stimulating hormone).2 It targets melanocortin receptors (specifically MC4-R) in the brain to treat Hypoactive Sexual Desire Disorder (HSDD) in women and is used off-label for erectile dysfunction in men.3 FDA-approved as Vyleesi for HSDD in women.4
- Dosing: Therapeutic doses are typically 1.75 mg (Vyleesi pen) or research doses of 1-2 mg administered as needed before sexual activity.
- Route: Subcutaneous (SC) injection or sometimes Intranasal spray.5
- Side Effects: Nausea (very common), flushing, headache, and a temporary increase in blood pressure.6
- Risks: Risk of Hypertension (high blood pressure) and potential for darkening of the skin/gums (hyperpigmentation) with long-term or high-dose use.7 Unregulated sourcing poses a significant purity risk.
- Description: A naturally occurring peptide that acts as a potent upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating the release of GnRH (Gonadotropin-Releasing Hormone), leading to an increase in LH and FSH, and subsequently testosterone and estradiol.
- Dosing: Research protocols vary significantly, often using doses between 3 mcg/kg to 6.4 mcg/kg, administered a few hours before activity, or daily for endocrine modulation.
- Route: Subcutaneous (SC) injection or Intravenous (IV) infusion.
- Side Effects: Generally well-tolerated. May cause flushing or injection site reaction. Acute, high-dose administration may cause dizziness or headache.
- Risks: Not FDA-approved; risks include uncontrolled, transient surges in reproductive hormones and the general risk of using unregulated research compounds.
Miscellaneous
- Description: A synthetic peptide analog of $\alpha$-MSH (alpha-melanocyte-stimulating hormone). It is an agonist of the melanocortin receptors (primarily MC1), used clinically to increase melanin production to protect skin from light damage in patients with Erythropoietic Protoporphyria (EPP).
- Dosing: For EPP, the FDA-approved protocol uses a 16 mg implant inserted Subcutaneously (SC) every two months. Research/unregulated protocols for tanning often cite doses of 0.5 mg to 1.0 mg daily or every other day.
- Route: Subcutaneous (SC) dissolvable implant (FDA-approved); or Subcutaneous (SC) injection (unregulated research use).
- Side Effects: Most commonly observed side effect is hyperpigmentation (skin darkening/tanning). Other effects include nausea, headache, flu-like symptoms, and injection site reaction.
- Risks: FDA-approved drug for specific medical conditions only. Risks for unauthorized use include unregulated purity, injection site complications, and unknown long-term effects of increased melanogenesis outside of clinical monitoring.
- Description: A synthetic analog of $\alpha$-MSH (alpha-melanocyte-stimulating hormone) that activates melanocortin receptors (MC1, MC3, MC4). Used to promote skin tanning and as an aphrodisiac (sexual arousal).
- Dosing: Starts very low (50 mcg) and titrates up, typically to 250-1000 mcg per day for desired effect.
- Route: Subcutaneous (SC) injection.
- Side Effects: Nausea (very common), facial flushing, decreased appetite, spontaneous erections (in men), and the development of new or darker moles/freckles.
- Risks: FDA Category 2 substance (compounding restricted); severe risks including blood pressure fluctuations, systemic toxicity (rhabdomyolysis, kidney issues reported), and unknown long-term risk for melanoma.
- Description: A naturally occurring tripeptide composed of glycine, cysteine, and glutamic acid. It is the body's master antioxidant, critical for detoxification, immune function, and protecting cells from oxidative stress.
- Dosing: IV/Injectable: Clinical doses typically range from 600 mg to 2000 mg per session. Oral: Doses range from 500 mg to 1000 mg per day.
- Route: Intravenous (IV) infusion (for maximum bioavailability), Intramuscular (IM) injection, Oral capsules, or Liposomal liquid (for better oral absorption).
- Side Effects: Generally well-tolerated. High doses via IV can cause transient mild nausea, cramping, or flushing. Rare instances of asthma/bronchospasm have been reported, primarily with inhaled forms.
- Risks: Very low risk when administered correctly. Main risks relate to adverse reactions if the IV or injection is improperly administered, or if the product is contaminated.
- Description: A synthetic tetrapeptide studied for its potential to activate telomerase (the enzyme that maintains telomere length) and modulate circadian rhythms, suggesting anti-aging and immune benefits.
- Dosing: Research protocols vary widely, often using 5-10 mg per day for short cycles (e.g., 10-20 days, repeated 2-4 times per year).
- Route: Subcutaneous (SC) injection or Intramuscular (IM) injection.
- Side Effects: Generally considered well-tolerated with no severe side effects commonly reported in human studies; minor injection site discomfort.
- Risks: Not FDA-approved; efficacy is highly speculative in humans, and risks are tied to the unregulated purity and quality of the synthesized compound.
- HGH
- Reta (my whole transformation is built off of reta)
- MT2 (coloring, 100x faster tan rate, less uv exposure)
tags:
BastiHgh
Biomaxx
